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Abstract
Aims: Stereotactic radiosurgery is increasingly used to treat multiple (four or more) brain metastases. Preserving cognitive functions is a highly relevant
treatment goal because cognitive deteriorations may negatively affect a patient’s quality of life. The aim of this study was to assess cognitive change, at the group
and individual level, in patients with 1 to 10 brain metastases up to 9 months after Gamma Knife radiosurgery (GKRS).
Materials and methods: Ninety-two patients with 1 to 10 newly diagnosed brain metastases, expected survival >3 months and Karnofsky Performance Status
(KPS) 70 and 104 non-cancer controls were included. A neuropsychological test battery was administered before GKRS (n ¼ 92) and at 3 (n ¼ 66), 6 (n ¼ 52)
and 9 (n ¼ 41) months after GKRS. The course of test performances, while taking into account practice effects, was analysed using linear mixed models. Pre-
GKRS predictors of cognitive trajectories were analysed. To determine proportions of individuals with cognitive changes, reliable change indices, with correction
for practice effects, were calculated.
Results: At the group level, immediate memory, working memory and information processing speed significantly improved over 9 months after GKRS. There
were no cognitive declines. Neither number nor volume of brain metastases influenced cognitive change over time. At the individual level, proportions of
patients with stable, improved or declined performances were comparable with controls, except for information processing speed (more individuals with
improvements in patients) and motor dexterity (more improvements and declines in patients).
Conclusions: Cognitive functioning in patients with 1 to 10 brain metastases was preserved, or improved, up to 9 months after GKRS. Neither number nor
volume of brain metastases influenced cognitive performance.
 2021 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Life expectancy in patients with brain metastases is
increasing due to improvements in systemic treatments of
the primary tumour [1,2]. Already before brain metastases
treatment, patients may suffer from cognitive impairments
caused by an interplay of factors, including the brain me-
tastases themselves, the primary tumour and itsAuthor for correspondence: W.C.M. Schimmel, Prof. Cobbenhagenlaan
225, Simon Building, Room S221, 5037 DB, Tilburg, the Netherlands. Tel:
þ31-13-466-3118.
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0936-6555/ 2021 The Royal College of Radiologists. Published by Elsevier Ltd. Th
org/licenses/by/4.0/).treatments, and the patient’s functional status [3,4]. These
impairments often concern slow processing of information
and memory problems and may negatively affect daily
functioning and quality of life [3].
A review on the cognitive effects after stereotactic radi-
osurgery (SRS) concluded that patients with brain metas-
tases experience little to no objective cognitive decline in
the early phase after SRS, followed by a trend towards
improvement or stabilisation up to 12 months after SRS [5].
Furthermore, evaluation of individual cognitive changes
after SRS showed that in most patients with brain metas-
tases, cognitive functions remained stable for at least 6 or 12
months after SRS [6,7].is is an open access article under the CC BY license (http://creativecommons.
W.C.M. Schimmel et al. / Clinical Oncology 33 (2021) 314e321 315In recent years, the total volume of brain metastases has
become a more prominent eligibility criterion for SRS as
opposed to the absolute number of brain metastases [8].
Although the application of SRS is rapidly expanding to
patients with multiple (more than four) brain metastases,
previous studies on cognitive outcomes after SRS mostly
included patients with a limited number of brain metas-
tases (one to four). These studies found no association,
based on univariate analyses and uncorrected for multiple
testing, between the number of brain metastases and
cognitive test performance, whereas higher total brain
metastases volume was significantly associated with
worse attention, information processing and executive
functions [4,9].
Cognitive outcomes after SRS in patients with more than
four brain metastases, as measured with an objective neu-
ropsychological test battery, have not been evaluated thus
far. Only one recent study, which used the Hopkins Verbal
Learning Test as a single neuropsychological test, reported
on stablememory performance up to 12months after SRS in
most patients with multiple (>10) brain metastases [7].
Furthermore, none of the previous studies corrected for
potential practice effects (i.e. improvements in perfor-
mances due to familiarity with test items and test proced-
ures [10,11]). Practice effects should be taken into account to
avoid a potential underestimation of cognitive decline, even
when using parallel/alternative versions of the same test
[10,11].
The aim of this study was to evaluate group and indi-
vidual cognitive change, while taking into account practice
effects, in patients with 1 to 10 brain metastases up to 9
months after Gamma Knife radiosurgery (GKRS). If cogni-
tive functioning could be preserved at the pre-treatment
level, this would suggest that GKRS does not cause addi-
tional cognitive decline. In addition, potential predictors of
cognitive performance over time were analysed.Materials and Methods
Cognition and Radiation-Study A (CAR-Study A;
NCT02953756) is a prospective observational study andwas
approved by the Medical Ethics Committee Brabant
(NL53472.028.15). We previously described baseline
cognitive performances and health-related quality of life
(HRQoL), and the course of fatigue in this patient group
[12e14].
Patients and Procedures
Patients with 1 to 10 newly diagnosed brain metastases
(total volume 30 cm3), Karnofsky Performance Status
(KPS)70 and expected survival>3months were recruited.
Additional eligibility criteria and procedures have previ-
ously been described [12,14].
A baseline neuropsychological assessment (NPA),
including neuropsychological tests and questionnaires on
anxiety and depression, fatigue and HRQoL, was carried out
in the morning before GKRS. Follow-up assessments,combinedwith clinical follow-ups, were carried out 3, 6 and
9 months after GKRS. All patients gave written informed
consent before the first NPA.Non-cancer Controls and Procedures
For normative purposes, non-cancer controls [13,14]
were recruited from the general community and the broad
network of the research group. Controls were selected to be,
as much as possible, comparable with the general popula-
tion and our patient group (frequency matching). Exclusion
criteria included a (history of) cancer diagnosis or severe
cerebrovascular disease in the past 12 months. Follow-up
assessments were carried out at 3 and 6 months after the
first NPA.Treatment
GKRS was carried out with a Leksell Gamma Knife
ICON (Elekta Instruments AB, Stockholm, Sweden). All
patients received a dose of 18e25 Gy with 99e100%
coverage of the target. Given the high conformity and
selectivity of GKRS, organs at risk (brainstem, optic nerves
and chiasm) were only segmented and optimised in the
GKRS planning workflow when relevant. Dose limits for
these organs were 18 Gy for the brainstem and 8 Gy for the
optic nerves and chiasm. No attempt was made to delineate
the hippocampus nor was there a dose limit set for the
hippocampus.Measures
Sociodemographic and clinical characteristics were
retrieved from patients’ medical health records. Cognitive
functioning was measured with a well-established battery,
including six neuropsychological tests: Hopkins Verbal
Learning Test-Revised with six parallel versions (immediate
and delayed verbal memory and recognition), Trail Making
Test (TMT-A; psychomotor speed and TMT-B; cognitive
flexibility), Controlled Oral Word Association with two
parallel versions (COWA; word fluency), Wechsler Adult
Intelligence Scale (WAIS) Digit Span (attention span and
working memory), WAIS Digit Symbol (information pro-
cessing speed) and Grooved Pegboard (dominant and non-
dominant hand dexterity) [3,15].
The total volumetric sum of contrast-enhancing brain
metastases was determined at baseline and at 3, 6 and 9
months after GKRS, using T1-weighted, contrast-enhanced
magnetic resonance imaging (MRI) scans (1.5 mm slice
thickness). A complete response was defined as a disap-
pearance of all brainmetastases (no longer visible). A partial
response was defined as a 65% decrease in total tumour
volume and no new brain metastases. Intracranial pro-
gression was defined as a 73% increase in total tumour
volume or new brainmetastases. Stable diseasewas defined
as no complete response, no partial response and no
intracranial progression [16].
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Statistical analyses were carried out with SPSS version
25, except for the linear mixed models (LMMs), which were
performed with R, version 3.6.1 [17].
Independent samples t-tests and chi-squared tests were
carried out to compare characteristics of patients with and
without at least one follow-up NPA. KaplaneMeier curves
were used to analyse overall survival. Cognitive changes
were determined between baseline (pre-GKRS) and 9
months (T0eT9), and for three separate time intervals:
baseline and 3 months (T0eT3), 3 and 6 months (T3eT6),
and 6 and 9 months (T6eT9).
Raw cognitive test scores were converted into socio-
demographically adjusted z scores based on data from our
control group (including age, sex and education as cova-
riates): z score ¼ Yo e Yp/SDresidual. Yo is the individual’s raw
test score, Yp is the predicted raw test score using regression-
based formulae and SDresidual is the standard deviation of the
control group’s residual [18]. For the TMT, the raw test score
on TMT-A was entered as a fourth predictor variable to
calculate the z score on TMT-B (the interference index TMT-
B|A).
To correct for practice effects for the 3-, 6- and 9-month
follow-up data, patients’ post-GKRS z scores were calcu-
lated using the controls’ test scores at 3 months, as the
strongest practice effects occur within this time interval
[10,19]. Except for the COWA, as each of the two parallel
versions has a different set of letters, we used the controls’
performance at 6months to calculate post-GKRS z scores for
patients at 6 months (a comparison with the same set of
letters). An impaired test performance was defined as a z
score e1.50 [20]. One-sample z-tests were used to
compare mean cognitive function of patients with controls
at baseline and at 9 months. Chi-squared tests were carried
out to compare the percentages of impaired test perfor-
mance of patients with controls at each time point. Inde-
pendent samples t-tests were used to compare cognitive
test performances between patients with and without
intracranial progression for each time point separately.
We used the nlme package [21] in R [17] to run 11 LMMs
of the relationship between performance on each cognitive
test and time. To estimate model parameters, the restricted
maximum likelihood estimate (REML) method was used.
The Akaike Information Criterion (AIC) and Bayesian Infor-
mation Criterion (BIC) were used to estimate model fit. As
random effects, the intercepts for the effect of cognition
were used. Random slopes were added for psychomotor
speed only. The first-order autoregressive covariance
structure (AR1) at level 1 and a scaled identity matrix at
level 2 was used. Timewas included as a categorical variable
in subsequent models to examine changes in cognitive
functioning for the separate time intervals.
These LMMs were also used to examine the interaction
effects between time and possible baseline predictors of
cognition. The following predictors, based on results fromprevious studies [4,14], were analysed: KPS (low 70e80
versus high 90e100), systemic treatment before or at time
of GKRS (yes versus no), total volume of brain metastases
(small <4.8 cm3, medium 4.8e12.6 cm3, large >12.6 cm3)
and number of brain metastases (one to three versus four
to 10).
Reliable change indices (RCIs), reflecting change at the
individual level in the context of observed changes in the
control group, correcting for measurement errors
(including practice effects) were calculated according to
formula 10 by Maassen et al. [22]. A change in test score
from baseline to follow-up was considered reliable if it fell
outside of the 90% confidence interval, corresponding to RCI
values above þ1.645 (improved performance) or below
e1.645 (declined performance). RCI values that did not
exceed these values were defined as ‘stable’ (no significant
change). At the test level, numbers of patients with
improved, stable or declined cognitive performance were
then counted for each test at each time interval.
Patients were categorised, based on the RCIs, into four
categories: (i) ‘decline’ (2 declines and 1 improvement
on any of the 11 test variables); (ii) ‘improvement’ (2
improvements and 1 decline); (iii) ‘both’ (2 declines and
2 improvements); (iv) ‘stable’ (1 declines and 1 im-
provements). Chi-squared or Fisher exact tests were con-
ducted to compare the proportions of participants in each
category between patients and controls. For T0eT9 and
T6eT9, the proportions of patients were compared with the
proportions of controls between T0eT6 and T3eT6,
respectively.
To control for the false discovery rate due to multiple
testing, a corrected alpha, based on the procedure of Ben-
jamini and Hochberg [23], was used per hypothesis.Results
Characteristics and Compliance
In total, 92 patients and 104 controls were included
(Table 1). Patients and controls did not differ in sex, age and
education. Forty per cent of patients had four to 10 brain
metastases. The 1-year survival rate was 48.9% and the
median overall survival was 11.8 months. The cognitive
tests were completed by 66 of 76 (86.8%), 52 of 68 (76.5%)
and 41 of 57 (71.9%) patients alive at 3, 6 and 9 months,
respectively. Reasons for dropout, apart from death (n¼ 24),
were: NPA was considered too burdensome (n ¼ 13), no
follow-up MRI scan as it was not clinically meaningful due
to poor neurological/physical condition (n¼ 12) and follow-
up elsewhere (n ¼ 2). Of the 66 patients with at least one
follow-up, 34 patients (51.5%) had intracranial progression
(in 18 patients due to new lesions only; 52.9%), 15 patients
(22.7%) had a partial or a complete response and 17 patients
(25.8%) had stable disease between time of treatment and
last follow-up. Clinical characteristics did not significantly
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without (n¼ 26) versus patients with at least one follow-up
NPA (n ¼ 66) had shorter survival (2.7 versus 17.1 months, p
< .001).
Cognitive Status at Baseline and at 9 Months e Group and
Individual Level
At baseline, patients performed significantly worse on all
tests compared with controls (p< .05; range mean z scores:
e0.21 to e1.63; supplementary Table S1 summarises the
mean z scores). The lowest mean scores were found for
non-dominant hand dexterity, cognitive flexibility and in-
formation processing speed. At 9 months after GKRS, pa-
tients performed significantly worse than controls on seven
of 11 tests (p < .03; range mean z scores: e0.49 to e1.40).
The lowest performances were found for dominant and
non-dominant hand dexterity, information processing
speed and psychomotor speed. Mean cognitive test perfor-
mances were comparable for patients with or without
intracranial progression at 3 (n ¼ 14 versus n ¼ 52), 6 (n ¼
17 versus n ¼ 35) and 9 months (n ¼ 17 versus n ¼ 24) after
GKRS (data not shown). At the individual level, significantly
more patients had impaired performances than controls: at
baseline for nine (15.2e55.3%) of 11 tests (p  .04) and at 9
months for seven (22.0e32.4%) of 11 tests (p < .03;
supplementary Table S2 summarises the percentages of
impaired performances for patients and controls).
Change in Cognitive Performance e Group Level
Over 9 months, cognitive performance remained stable,
except for significant improvements in immediate memory,
working memory and information processing speed. More
specifically, working memory improved significantly be-
tween baseline and 3 months, and information processing
speed improved significantly between 3 and 6 months.
Although verbal recognition and verbal fluency did not
change over 9 months, verbal recognition improved
significantly between 3 and 6 months and decreased
significantly between 6 and 9 months; the reverse was
observed for verbal fluency (first decrease, and then
improvement) (Table 2).
Predictors of Cognitive Performance over Time e Group Level
Patients with low (versus high) KPS had significantly
more improvement over time in verbal recognition. No
other significant predictors were found. Neither number
nor volume of brain metastases influenced cognitive per-
formance over time (supplementary Table S3 shows the
linear mixed model results for the baseline predictors of
cognitive performances over time).
Individual Change in Cognitive Performance e Test Level
Although the proportions of patients with declined,
stable or improved performance at the test level fluctuated
across the time intervals, there were no significantdifferences in proportions between patients and controls,
except for information processing speed, and dominant and
non-dominant hand dexterity (see Figure 1 and
supplementary Tables S4 and S5, which summarise the in-
dividual cognitive changes in patients and controls,
respectively). For information processing speed, over 9
months, and especially in the first 3 months post-GKRS,
significantly more patients (versus controls) had improved
performance (24.3% and 11.7%), and significantly fewer pa-
tients had stable scores (70.3% and 81.7%). For dominant
hand dexterity, significantly more patients had declined
(16.4%) or improved (18.0%) performance in the first 3
months only. For non-dominant hand dexterity, signifi-
cantly more patients had declined (24.4%) or improved
(26.8%) performance over 9 months.
Individual Change in Cognitive Performance e Patient Level
Over 9 months, test performance remained stable in
39.4% of patients and improved in 33.3% of patients; 21.2% of
patients showed a decline and 6.1% of patients had both
improvements and declines (Figure 2). Compared with
controls, significantly fewer patients had stable perfor-
mance (39.4% versus 77.0%) and more patients showed an
improvement in test performance (33.3% versus 13.1%).
Regarding the separate time intervals, 63.5e73.3% of the
patients had stable test performances and 15.4e23.5% of
patients had declined test performances. Improved perfor-
mances were found in 11.1e21.2% of patients (no patients
were categorised as ‘both’; Figure 2). There were no sig-
nificant differences in the proportions of patients and
controls with declined, stable or improved test perfor-
mances (p-values > .14; data not shown).Discussion
In this study, we evaluated group and individual level
cognitive performance, corrected for practice effects, up to 9
months after GKRS in patients with up to 10 brain metas-
tases. Already at baseline, mean performances were worse
in patients on all cognitive tests compared with controls,
and at the individual level, percentages of impairment were
significantly higher for most tests.
Over 9 months after GKRS, patients’ performances
improved for immediate verbal memory, working memory
and information processing speed. Performances on all
other measures remained stable. Previous studies showed
little to no objective cognitive decline after SRS in patients
with one up to four brain metastases [4,9,24]. Compared
with our study, these studies had a shorter follow-up and/or
smaller patient samples at follow-up. None of the previous
studies on cognitive functioning of patients with brain
metastases after SRS took practice effects into account [5],
which could have led to a potential underestimation of
cognitive decline [10,11]. In our study, with correction for
practice effects, still no decline in group performances over
9 months were found in patients with 1 to 10 brain me-













Participants included, n (%) 92 (100%) 104 (100%) 66 (72%) 26 (28%)
Sex, male, n (%) 47 (51%) 50 (48%) 31 (47%) 16 (62%)
Age in years, mean  SD (range) 62  10 (31e80) 60  10 (31e87) 62  9 (31e80) 61  11 (39e76)
Educational level, n (%)*
Low 28 (30%) 25 (24%) 16 (24%) 12 (46%)
Middle 37 (40%) 33 (32%) 30 (46%) 7 (27%)
High 27 (29%) 46 (44%) 20 (30%) 7 (27%)
KPS, n (%)
70e80 33 (36%) NA 21 (32%) 12 (46%)
90e100 59 (64%) 45 (68%) 14 (54%)
GPA
Class 2 15 (16%) NA 13 (20%) 2 (8%)
Class 3 60 (65%) 41 (62%) 19 (73%)
Class 4 17 (19%) 12 (18%) 5 (19%)
Number of brain metastases, n (%)
1e3 55 (60%) NA 42 (64%) 13 (50%)
4e10 37 (40%) 24 (36%) 13 (50%)
Total volume of brain metastases,
median (range)y,z
5.6 (0.02e31.1) NA 5.9 (0.02e31.1) 5.3 (0.04e31.0)
Small (<4.8 cm3) 40 (44%) 28 (42%) 12 (46%)
Middle (4.8e12.6 cm3) 25 (27%) 17 (26%) 8 (31%)
Large (>12.6 cm3) 27 (29%) 21 (32%) 6 (23%)
Primary tumour, n (%)
Lung 55 (60%) NA 40 (61%) 15 (58%)
Renal 15 (16%) 11 (17%) 4 (15%)
Melanoma 12 (13%) 7 (11%) 5 (19%)
Other 10 (11%) 8 (12%) 2 (8%)
Systemic therapyx
No 39 (42%) NA 28 (42%) 11 (42%)
Yes 53 (58%) 38 (58%) 15 (58%)
Chemotherapy|| 37 (40%) 28 (42%) 9 (35%)
Median overall survival (months)
(95% confidence interval)
11.8 (8.6e15.0){ NA 17.1 (10.6e23.7)** 2.7 (1.7e3.7)yy
GPA, graded prognostic assessment; KPS, Karnofsky Performance Status; NA, not applicable; NPA, neuropsychological assessment; SD,
standard deviation.
* Educational level (Verhage [31]; seven levels): low ¼ 1e4; middle ¼ 5; high ¼ 6e7.
y By patient (one patient had a total tumour volume 31.1 cm3 on the planning magnetic resonance imaging scan).
z Nineteen of 92 (21%) patients had a total volume of brain metastases >15 cm3.
x Before or at time of Gamma Knife radiosurgery.
|| Alone only or in combination with other systemic therapies.
{ Twenty-seven patients censored (29.3%).
** Twenty-five patients censored (37.9%).
yy Two patients censored (7.7%).
Percentages may not add up to 100% due to rounding.
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indicates that although the overall course remained stable
up to 9 months after GKRS, fluctuations in test perfor-
mances at the group level do occur within the intervals.
Baseline KPS influenced change in test performance for
only one of 11 tests (more improvement over time in verbal
recognition in patients with lower baseline KPS). In line
with previous studies [4], the number of brain metastases
did not influence cognitive change over time in multivariate
analyses. Neither did we find a statistically significant as-
sociation between brain metastases volume and change in
cognitive performance. This is in contrast with previousstudies based on univariate analyses that found significant
negative associations between total brain metastases vol-
ume and attention, information processing and executive
functions [4,9].
In accordance with the results at group level, and with
van der Meer et al. [6], for most patients, both at the patient
level and at the test level, cognitive functioning remained
stable or improved over 9 months after GKRS, except for
non-dominant hand dexterity. Performance on non-
dominant hand dexterity, a measure that was not
included in the study of van der Meer et al. [6], varied
considerably at the individual level: therewere significantly
Table 2
Course of cognitive functioning in patients with brain metastases after radiosurgery
Time slope T0eT9 Interval T0eT3 Interval T3eT6 Interval T6eT9
Beta (SE) F-value P* Beta (SE) Beta (SE) Beta (SE)
Immediate verbal memory 0.16 (0.1) 7.282 .008 0.28 (0.1) 0.09 (0.1) 0.08 (0.2)
Delayed verbal memory e0.01 (0.0) 0.022 .883 0.09 (0.1) e0.04 (0.1) e0.09 (0.2)
Verbal recognition 0.09 (0.1) 3.224 .075 0.13 (0.1) 0.52 (0.2) e0.62 (0.2)
Psychomotor speed e0.04 (0.1) 0.202 .654 e0.38 (0.2) 0.14 (0.2) 0.17 (0.2)
Cognitive flexibility 0.23 (0.1) 3.358 .069 0.57 (0.3) 0.25 (0.3) e0.27 (0.3)
Verbal fluency e0.08 (0.0) 3.479 .064 e0.12 (0.1) e0.32 (0.1) 0.33 (0.1)
Attention span e0.04 (0.0) 1.590 .209 e0.14 (0.1) 0.09 (0.1) e0.11 (0.1)
Working memory 0.22 (0.1) 19.295 <.001 0.52 (0.1) 0.08 (0.1) 0.03 (0.2)
Information processing speed 0.17 (0.0) 15.333 <.001 0.12 (0.1) 0.33 (0.1) 0.00 (0.1)
Dominant hand dexterity 0.06 (0.1) 0.277 .600 0.27 (0.2) 0.20 (0.3) e0.42 (0.3)
Non-dominant hand dexterity 0.04 (0.1) 0.230 .633 0.13 (0.2) 0.24 (0.2) e0.38 (0.3)
* Corrected alphas, using the Benjamini and Hochberg [23] procedure, were 0.014 for the overall models (time slope T0eT9), 0.033 for the
time intervals of verbal recognition and verbal fluency, and 0.017 for the time intervals of the other cognitive tests. Bold type indicates
statistical significance. T0 ¼ baseline, T3, T6, T9 ¼ 3, 6, 9 months.
W.C.M. Schimmel et al. / Clinical Oncology 33 (2021) 314e321 319more improvements as well as more declines in patients as
compared with controls. The individual variations in motor
dexterity were not reflected in our group-level results. This
underlines the importance of individual-level analyses in
addition to group-level analyses as the latter can mask in-
dividual cognitive changes. Regarding the separate time
intervals, no significant differences were found between
patients and controls in proportions of change except for
information processing speed (more improvement in pa-
tients) and dominant hand dexterity (more improvement
and decline in patients) during the first 3 months after
GKRS.
At 9 months, performances on most tests, except for the
memory tasks (including working memory), were still
significantly below the normative mean of non-cancer
controls. The lowest performances were found forFig 1. Individual cognitive changes at the test level over 9 months after rad
significant difference in the proportions of patients and controls with de
centage is significantly higher/lower in patients compared with controls)psychomotor speed, information processing speed, and
dominant and non-dominant hand dexterity. Also, fre-
quencies of impairment were significantly higher in pa-
tients than in controls for most tests. These frequencies
were highest for cognitive flexibility, information pro-
cessing speed and dominant hand dexterity. This illus-
trates the persistent character of cognitive impairments
that were already present before brain metastases treat-
ment. The impairments in dominant hand dexterity may
have negatively influenced performance on the other
cognitive tasks (such as the TMT and Digit Symbol) with
high motor demands [25] and may partially explain the
impaired performance on psychomotor speed, cognitive
flexibility and information processing. In addition,
chemotherapy and certain targeted therapies can cause
peripheral neuropathy in some patients [26], which mayiosurgery (T0eT9; n ¼ 36e41). Note: bold text indicates a statistically
clined, stable or improved performance (þ/e indicates that the per-
.
Fig 2. Reliable cognitive changes after radiosurgery at the individual patient level. Note: patient-level categories: (i) ‘decline’ (2 decline and 1
improvements on any of the 11 test variables); (ii) ‘improvement’ (2 improvement and 1 declines); (iii) ‘both’ (2 decline and 2
improvement); (iv) ‘stable’ (1 declines and 1 improvements). Bold text indicates a statistically significant difference in the proportions of
patients and controls with declined, stable or improved performance (þ/e indicates that the percentages were significantly higher (þ) or lower
(e) in patients compared with controls).
W.C.M. Schimmel et al. / Clinical Oncology 33 (2021) 314e321320also partially explain the impaired performance on these
tasks with motor output.
Cognitive impairments may seriously worsen the ability
to carry out everyday life activities and impair patients’
quality of life. Patients may encounter difficulties with
processing (new) information, switching between tasks,
remembering new information, performing adequate
movements appropriate to a certain task, and with the
ability to reason through medical treatment decisions [27].
Additionally, patients may experience time pressure, and
over-stimulation, which makes it harder to engage in, and
enjoy, social interactions with others. These difficulties may
also increase the caregiver burden [28]. Cognitive in-
terventions, such as rehabilitation programmes [29], may
improve the quality of life/survival in these patients, espe-
cially for subgroups of patients with brain metastases who
have a longer life expectancy.
This study has limitations to consider. We included a
heterogeneous study sample of patients with brain metas-
tases originating from different primary cancers. The study
sample as a whole is, however, representative for the group
of patients with brain metastases that is generally treated
with GKRS. Patients who were willing and able to partici-
pate in this study may have been more resilient compared
with non-participating patients and consequentlymay have
performed better than non-participating patients. More-
over, although mean differences in baseline test perfor-
mances and clinical characteristics between patients with
and those without follow-up assessments were not statis-
tically significant, it is likely that patients who completed
the assessment at 9 months were the ‘better performing’
patients in terms of functional status and cognitive func-
tioning. Additionally, the NPA was administered in the
morning before treatment and at clinical follow-ups
(including MRI scan and consult), during which patients
may have experienced anxiety or depression. However,
although patients had elevated levels of anxiety and
depression, we found no evidence for a direct effect of
anxiety and depression on cognitive test performance atbaseline [14]. This is in line with a study by Gerstenecker
et al. [30] in patients with brain metastases and suggests
that both anxiety and depression may not be primary con-
tributors for cognitive impairment in these patients [14,30].
Furthermore, despite the correction for practice effects and
the use of parallel versions, an additional practice effect
may have occurred at 9 months because these patients may
have been evenmore familiarisedwith the tests and the test
procedures compared with the assessments at 3 or 6
months.
To conclude, up to 9 months after initial GKRS, both at
the group and individual level, most patients with 1 to 10
brain metastases showed preserved or improved cognitive
functioning. This suggests that GKRS does not cause addi-
tional cognitive damage. Neither number nor volume of
brain metastases influenced cognitive performance.Conflicts of Interest
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